NO20072296L - Fremgangsmater og systemer for prognose og behandling av faste tumorer - Google Patents
Fremgangsmater og systemer for prognose og behandling av faste tumorerInfo
- Publication number
- NO20072296L NO20072296L NO20072296A NO20072296A NO20072296L NO 20072296 L NO20072296 L NO 20072296L NO 20072296 A NO20072296 A NO 20072296A NO 20072296 A NO20072296 A NO 20072296A NO 20072296 L NO20072296 L NO 20072296L
- Authority
- NO
- Norway
- Prior art keywords
- genes
- treatment
- rcc
- prognosis
- systems
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 2
- 230000002596 correlated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62968104P | 2004-11-22 | 2004-11-22 | |
| PCT/US2005/042591 WO2006060265A2 (en) | 2004-11-22 | 2005-11-22 | Methods and systems for prognosis and treatment of solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072296L true NO20072296L (no) | 2007-08-20 |
Family
ID=36463527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072296A NO20072296L (no) | 2004-11-22 | 2007-05-03 | Fremgangsmater og systemer for prognose og behandling av faste tumorer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060134671A1 (ja) |
| EP (1) | EP1815024A2 (ja) |
| JP (1) | JP2008520251A (ja) |
| KR (1) | KR20070084488A (ja) |
| CN (1) | CN101068936A (ja) |
| AU (1) | AU2005312081A1 (ja) |
| BR (1) | BRPI0518036A (ja) |
| CA (1) | CA2588253A1 (ja) |
| CR (1) | CR9100A (ja) |
| IL (1) | IL182813A0 (ja) |
| MX (1) | MX2007005764A (ja) |
| NI (1) | NI200700126A (ja) |
| NO (1) | NO20072296L (ja) |
| RU (1) | RU2007117507A (ja) |
| WO (1) | WO2006060265A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235395A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| GB0717101D0 (en) * | 2007-09-03 | 2007-10-10 | Cambridge Entpr Ltd | Tumour marker |
| EP2265328B1 (en) * | 2008-03-20 | 2018-05-09 | EBS Technologies GmbH | An apparatus for automatic treatment adjustment after nervous system dysfunction |
| WO2011150976A1 (en) | 2010-06-04 | 2011-12-08 | bioMérieux | Method and kit for the prognosis of colorectal cancer |
| WO2011153684A1 (en) * | 2010-06-08 | 2011-12-15 | Biomerieux | Method and kit for the prognosis of colorectal cancer |
| CN106148508B (zh) * | 2010-06-08 | 2019-12-03 | 生物梅里埃公司 | 用于结肠直肠癌预后的方法和试剂盒 |
| KR101437718B1 (ko) * | 2010-12-13 | 2014-09-11 | 사회복지법인 삼성생명공익재단 | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 |
| WO2012129758A1 (en) | 2011-03-25 | 2012-10-04 | Biomerieux | Method and kit for determining in vitro probability for individual to suffer from colorectal cancer |
| US20170109439A1 (en) * | 2014-06-03 | 2017-04-20 | Hewlett-Packard Development Company, L.P. | Document classification based on multiple meta-algorithmic patterns |
| US11193172B2 (en) * | 2015-01-09 | 2021-12-07 | Tokyo University Of Science Foundation | Method for predicting prognosis of patient with cancer or inflammatory disease |
| CN108624650B (zh) * | 2018-05-14 | 2022-04-29 | 乐普（北京）医疗器械股份有限公司 | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 |
| CN109355385B (zh) * | 2018-11-16 | 2022-02-08 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | Linc00266-1 rna作为实体瘤标志物的应用 |
| US11721441B2 (en) * | 2019-01-15 | 2023-08-08 | Merative Us L.P. | Determining drug effectiveness ranking for a patient using machine learning |
| CN110634571A (zh) * | 2019-09-20 | 2019-12-31 | 四川省人民医院 | 肝移植术后预后预测系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3944996B2 (ja) * | 1998-03-05 | 2007-07-18 | 株式会社日立製作所 | Ｄｎａプローブアレー |
| US6647341B1 (en) * | 1999-04-09 | 2003-11-11 | Whitehead Institute For Biomedical Research | Methods for classifying samples and ascertaining previously unknown classes |
| EP1242443A4 (en) * | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| US20030165854A1 (en) * | 2000-12-05 | 2003-09-04 | Cunningham Mary Jane | Marker genes responding to treatment with toxins |
| AU2004235395A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
-
2005
- 2005-11-22 RU RU2007117507/14A patent/RU2007117507A/ru not_active Application Discontinuation
- 2005-11-22 KR KR1020077011662A patent/KR20070084488A/ko not_active Application Discontinuation
- 2005-11-22 CA CA002588253A patent/CA2588253A1/en not_active Abandoned
- 2005-11-22 JP JP2007543490A patent/JP2008520251A/ja active Pending
- 2005-11-22 AU AU2005312081A patent/AU2005312081A1/en not_active Abandoned
- 2005-11-22 US US11/285,502 patent/US20060134671A1/en not_active Abandoned
- 2005-11-22 MX MX2007005764A patent/MX2007005764A/es not_active Application Discontinuation
- 2005-11-22 BR BRPI0518036-8A patent/BRPI0518036A/pt not_active IP Right Cessation
- 2005-11-22 EP EP05852117A patent/EP1815024A2/en not_active Withdrawn
- 2005-11-22 CN CNA200580039290XA patent/CN101068936A/zh active Pending
- 2005-11-22 WO PCT/US2005/042591 patent/WO2006060265A2/en active Application Filing
-
2007
- 2007-04-26 IL IL182813A patent/IL182813A0/en unknown
- 2007-05-03 NO NO20072296A patent/NO20072296L/no not_active Application Discontinuation
- 2007-05-04 CR CR9100A patent/CR9100A/es not_active Application Discontinuation
- 2007-05-17 NI NI200700126A patent/NI200700126A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006060265A2 (en) | 2006-06-08 |
| WO2006060265A3 (en) | 2007-01-04 |
| RU2007117507A (ru) | 2008-12-27 |
| AU2005312081A1 (en) | 2006-06-08 |
| JP2008520251A (ja) | 2008-06-19 |
| US20060134671A1 (en) | 2006-06-22 |
| EP1815024A2 (en) | 2007-08-08 |
| BRPI0518036A (pt) | 2008-10-28 |
| CA2588253A1 (en) | 2006-06-08 |
| MX2007005764A (es) | 2007-07-20 |
| NI200700126A (es) | 2008-05-09 |
| CN101068936A (zh) | 2007-11-07 |
| IL182813A0 (en) | 2007-08-19 |
| CR9100A (es) | 2007-08-28 |
| KR20070084488A (ko) | 2007-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072296L (no) | Fremgangsmater og systemer for prognose og behandling av faste tumorer | |
| NO20074104L (no) | Fremgangsmater og systemer for diagnose, prognose og seleksjon ved behandling av leukemi | |
| WO2004097052A3 (en) | Methods for prognosis and treatment of solid tumors | |
| Yu et al. | Hepatocellular carcinoma downstaging in liver transplantation | |
| Berger et al. | Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: oncological outcomes at 7 years | |
| Truong et al. | The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the MD Anderson Cancer Center | |
| WO2004048933A3 (en) | Methods for diagnosing rcc and other solid tumors | |
| Antonelli et al. | Surgical treatment of atypical metastasis from renal cell carcinoma (RCC) | |
| RU2013146242A (ru) | Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов | |
| Orsini et al. | Index of prolonged air leak score validation in case of video-assisted thoracoscopic surgery anatomical lung resection: results of a nationwide study based on the French national thoracic database, EPITHOR | |
| Chibuk et al. | Horizons in veterinary precision oncology: fundamentals of cancer genomics and applications of liquid biopsy for the detection, characterization, and management of cancer in dogs | |
| Kim et al. | Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma | |
| Hosokawa et al. | Recurrence patterns of esophagogastric junction adenocarcinoma according to Siewert's classification after radical resection | |
| Correa et al. | Small renal masses in close proximity to the collecting system and renal sinus are enriched for malignancy and high Fuhrman grade and should be considered for early intervention | |
| Hsueh et al. | Survival analysis in patients with upper urinary tract transitional cell carcinoma: a comparison between open and hand‐assisted laparoscopic nephroureterectomy | |
| Yen et al. | Factors predicting recurrence and postrecurrence survival in completely resected thymic carcinoma | |
| Karellas et al. | Advanced‐stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection | |
| Yap et al. | Predictors of early mortality after radical nephrectomy with renal vein or inferior vena cava thrombectomy-a population-based study. | |
| Villavicencio et al. | Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: management and results at long-term follow-up | |
| Chiu et al. | Prognosis of kidney transplant recipients with pretransplantation malignancy: a nationwide population-based cohort study in Taiwan | |
| Seery et al. | Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer | |
| Jeong et al. | Age at diagnosis is an independent predictor of small renal cell carcinoma recurrence-free survival | |
| Hernandez et al. | P16. 07 immuno-modulatory effects of ceralasertib in combination with durvalumab in NSCLC with progression on anti-PD (L) 1 treatment (HUDSON) | |
| Goertz et al. | Long-term outcome of 181 patients with Liposarcomas of the extremity and Truncal Wall | |
| Kwon et al. | Long-term oncologic outcomes after radical cystectomy for bladder cancer at a single institution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |